Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway

Fig. 2

BM-1197 induced dose- and time-dependent apoptosis. a. After treatment with different concentrations of BM-1197, apoptotic bodies with intense blue fluorescence (mainly apoptotic cells due to chromatin condensation, the nucleus was fragmented and densely) stained were observed. b. BM-1197 induces a dose- and time-dependent apoptosis in OCI-ly8 cellsdetected by Annexin V/PI staining and analyzed using flow cytometry. c. Quantification of the apoptotic rate after BM-1197 treatment with increasing dose. d. Quantification of the apoptotic rate after BM-1197 treatment with increasing time. e. After BM-1197 treatment at indicated time points, the change of Bcl-2 family proteins and apoptotic proteins. f. After BM-1197 treatment at indicated dose, the change of Bcl-2 family proteins and apoptotic proteins

Back to article page